Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/8276
Title: | Tovaxin, radiation-attenuated, patient-specific T-cells for the therapeutic vaccination of multiple sclerosis | Authors: | HELLINGS, Niels STINISSEN, Piet |
Issue Date: | 2008 | Publisher: | THOMSON SCIENTIFIC | Source: | CURRENT OPINION IN INVESTIGATIONAL DRUGS, 9(5). p. 534-540 | Abstract: | Opexa Pharmaceuticals Inc is developing Tovaxin, a trivalent formulation of attenuated myelin-peptide-reactive T-cells, for the potential treatment of multiple sclerosis. Tovaxin is being evaluated in phase II clinical trials. Opexa was previously investigating Tovaxin for the potential treatment of rheumatoid arthritis; however, no development has been reported for this indication since December 2002. | Notes: | Hasselt Univ, Biomed Res Inst, B-3590 Diepenbeek, Belgium. | Document URI: | http://hdl.handle.net/1942/8276 | ISSN: | 1472-4472 | ISI #: | 000255431300012 | Category: | A1 | Type: | Journal Contribution | Validations: | ecoom 2009 |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Tovaxin.pdf | Non Peer-reviewed author version | 107.36 kB | Adobe PDF | View/Open |
WEB OF SCIENCETM
Citations
1
checked on Sep 6, 2024
Page view(s)
14
checked on Sep 7, 2022
Download(s)
2
checked on Sep 7, 2022
Google ScholarTM
Check
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.